Hypersensitivity reaction to certolizumab pegol in a patient affected by psoriatic arthritis

Dermatol Ther. 2019 May;32(3):e12900. doi: 10.1111/dth.12900. Epub 2019 Apr 21.

Abstract

The pathogenic mechanism of hypersensitivity reactions (HSRs) to monoclonal antibodies is not fully understood. HSRs can occur after the first exposure or multiple exposures and include acute infusion reactions induced by cytokine release, besides Type I, Type III, and Type IV reactions.). We reported a case of anaphylactic reaction to certolizumab pegol in a patient affected by psoriatic arthritis and a possible management of this condition.

Keywords: certolizumab; hypersensitivity reaction; monoclonal antibodies.

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adult
  • Arthritis, Psoriatic / drug therapy*
  • Certolizumab Pegol / adverse effects*
  • Drug Hypersensitivity / etiology*
  • Female
  • Humans

Substances

  • Certolizumab Pegol